Targeting PD-L2–RGMb overcomes microbiome-related immunotherapy resistance
Harvard University · Boston VA Research Institute · +3 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
177
total citations
- FWCI
- 38.43
- Percentile
- 100%
- References
- 37
Citations per year
Authors
16- JSJoon Seok Park
Harvard University, Boston VA Research Institute
- FSFrancesca S. Gazzaniga
Harvard University, Massachusetts General Hospital, Boston VA Research Institute
- MWMeng–Huang Wu
Harvard University, Boston VA Research Institute
- AKAmalia K. Luthens
Harvard University, Boston VA Research Institute
- JEJacob E. Gillis
Harvard University, Boston VA Research Institute
Topics & keywords
Topics
Keywords
- Blockade
- Microbiome
- Immune checkpoint
- Immunity
- Immune system
- Downregulation and upregulation
- Immunology
- Antibody
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.
Funding
- BSBristol-Myers Squibb
- AAstraZeneca
- GGlaxoSmithKline
- CPCancer Prevention and Research Institute of TexasAward: RP210028
- GSGilead Sciences
- MModerna
- IIpsen
- NINational Institutes of HealthAwards: RP210028, P50CA206963, P50CA101942, P01 AI56299
- GGenentech
- NCNational Cancer InstituteAwards: P50CA101942, 5F32CA247072-02, P50CA206963